TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9419295

Group type: EXPERIMENTAL
Intervention: +ISC
Number of subjects: 50

Group type: COMPARATOR
Intervention: -ISC
Number of subjects: 50
Study: 10172484

Group type: EXPERIMENTAL
Intervention: lenograstim
Number of subjects: 162

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 162
Study: 2628131

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg orally twice daily for 10 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Amoxycillin 250 mg orally three times daily for 10 days
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil for acute on chronic sinusitis
Number of subjects: 160

Group type: COMPARATOR
Intervention: Amoxycillin for acute on chronic sinusitis
Number of subjects: 160
Study: 786190

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DMP)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Steroid-treated group (DMP + MPS)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (Saline)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (No steroid)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Steroid-treated patients (DMP + MPS)
Number of subjects: 500
Study: 31232076

Group type: EXPERIMENTAL
Intervention: Standard care + prehabilitation (nutritional support, control of diabetes and exocrine pancreatic insufficiency, physical and respiratory training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 28486086

Group type: EXPERIMENTAL
Intervention: Increasing-distance interval-training (100-200-300-400-500 m)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Decreasing-distance interval-training (500-400-300-200-100 m)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increasing-distance interval-training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Decreasing-distance interval-training
Number of subjects: 40
Study: 25890135

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Precision training
Number of subjects: 16
Study: 23497981

Group type: EXPERIMENTAL
Intervention: 1.5 μg/kg atomized dexmedetomidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (intranasal water)
Number of subjects: 18
Study: 21570054

Group type: EXPERIMENTAL
Intervention: Systemic cyclosporine (CsA) administered for at least 6 months with a blood CsA concentration of approximately 800 ng/mL.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no systemic cyclosporine).
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Systemic cyclosporine (CsA) administered for at least 6 months.
Number of subjects: 39
Study: 19232638

Group type: EXPERIMENTAL
Intervention: Sensory Adapted Environment (SAE)
Number of subjects: 35
Study: 17042889

Group type: EXPERIMENTAL
Intervention: l-carnitine (15 mg/kg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 60
Study: 12601631

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (3 years treatment)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 25
Study: 10604887

Group type: EXPERIMENTAL
Intervention: h5G1.1‐scFv at 2 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: h5G1.1‐scFv at 1 or 2 mg/kg
Number of subjects: 0
Study: 8542173

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant and primary medical treatment
Number of subjects: 0
Study: 1834835

Group type: EXPERIMENTAL
Intervention: Oxidized, regenerated cellulose absorbable adhesion barrier
Number of subjects: 80
Study: 6453908

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not treated with BCG
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal healthy volunteers
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 14
Study: 6140091

Group type: EXPERIMENTAL
Intervention: prenalterol (40 to 120 mg/day)
Number of subjects: 16
Study: 30936290

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) treatment
Number of subjects: 0
Study: 29482672

Group type: EXPERIMENTAL
Intervention: Fully slatted flooring (CS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fully slatted flooring covered with rubber strips (RS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fully slatted flooring during growing period and solid floor covered with straw bedding during finishing period (CS-S)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fully slatted flooring during growing period and fully slatted flooring covered with rubber strips during finishing period (CS-RS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (RS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (CS)
Number of subjects: 80
Study: 27253214

Group type: EXPERIMENTAL
Intervention: Group psychoeducation (GP) - 10 weekly sessions followed by 8 booster sessions over 2 years
Number of subjects: 85

Group type: COMPARATOR
Intervention: Individual psychoeducation (IP) - 3 sessions
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Group psychoeducation (GP) with comorbid harmful substance use (HSU)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Group psychoeducation (GP) without harmful substance use (HSU)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Group psychoeducation (GP)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Individual psychoeducation (IP)
Number of subjects: 85
Study: 25354581

Group type: EXPERIMENTAL
Intervention: 1xH5N1‐AS
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 2xH5N1‐AS
Number of subjects: 160

Group type: COMPARATOR
Intervention: 1xH5N1
Number of subjects: 160

Group type: COMPARATOR
Intervention: 2xH5N1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 1xH5N1‐AS (neutralising antibodies)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 2xH5N1‐AS (neutralising antibodies)
Number of subjects: 160
Study: 22565360

Group type: EXPERIMENTAL
Intervention: Upper extremity assistance during sit-to-stand (STS) task
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: No upper extremity assistance during sit-to-stand (STS) task
Number of subjects: 28
Study: 20392868

Group type: EXPERIMENTAL
Intervention: rhTSH
Number of subjects: 88

Group type: COMPARATOR
Intervention: hypothyroid
Number of subjects: 88
Study: 17555530

Group type: EXPERIMENTAL
Intervention: Weekly oral risedronate (35 mg) with vitamin D and calcium
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (vitamin D and calcium only)
Number of subjects: 84
Study: 15703503

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12432190

Group type: EXPERIMENTAL
Intervention: Azithromycin (5 days treatment)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Azithromycin (14 days treatment)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 13
Study: 10080586

Group type: EXPERIMENTAL
Intervention: Doxorubicin-based neoadjuvant chemotherapy
Number of subjects: 372
Study: 8551959

Group type: EXPERIMENTAL
Intervention: Amphotericin B (AB) alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amphotericin B (AB) + Itraconazole (IZ)
Number of subjects: 20
Study: 1776591

Group type: EXPERIMENTAL
Intervention: Chlormethiazole (384 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7030645

Group type: EXPERIMENTAL
Intervention: Amcinonide cream 0.1 percent
Number of subjects: 29

Group type: COMPARATOR
Intervention: Halcinonide cream 0.1 percent
Number of subjects: 29
Study: 31347002

Group type: EXPERIMENTAL
Intervention: Triple puncture treatment (6 times per week for 4 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Carbamazepine (300‐600 mg per day for at least 1 month)
Number of subjects: 64
Study: 29566104

Group type: EXPERIMENTAL
Intervention: Everolimus plus Letrozole (10 mg/d + 2.5 mg/d) in first-line treatment
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Everolimus plus Exemestane (10 mg/d + 25 mg/d) in second-line treatment
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Adverse events in first-line treatment
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Adverse events in second-line treatment
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Overall mortality during the study
Number of subjects: 202
Study: 27900992

Group type: EXPERIMENTAL
Intervention: Improved intermittent‐clamped drainage (ICD)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Continuous negative pressure drainage (CNPD)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 156
Study: 24860157

Group type: EXPERIMENTAL
Intervention: Ventilation strategy to achieve E'(CO₂) values of 40‐42 mm Hg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ventilation strategy to achieve E'(CO₂) values of 30‐32 mm Hg
Number of subjects: 70
Study: 22555350

Group type: EXPERIMENTAL
Intervention: Comprehensive oral care protocol (tongue scraping, electric toothbrushing, moisturizing)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard oral care protocol (manual toothbrushing)
Number of subjects: 56
Study: 20681276

Group type: EXPERIMENTAL
Intervention: Gingko biloba Tablet (GBT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (furosemide, spironolactone, and perindopril without GBT)
Number of subjects: 84
Study: 16949722

Group type: EXPERIMENTAL
Intervention: Graphic method of presenting information
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Written method of presenting information
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Interactive method of presenting information
Number of subjects: 150
Study: 16275189

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (50 to 70 mug/kg/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 30
Study: 12358999

Group type: EXPERIMENTAL
Intervention: Teachers in the target school
Number of subjects: 136

Group type: COMPARATOR
Intervention: Teachers in the control school
Number of subjects: 136

Group type: COMPARATOR
Intervention: Students
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Teachers with dry and crusty nasal mucosa
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Atopic and non-atopic subjects
Number of subjects: 136
Study: 10500058

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg once daily)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg once daily)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg 3 times daily)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study: 8953672

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g bolus dose)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Lymecycline (10-day course of 300 mg twice daily)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Lymecycline
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 146
Study: 1834805

Group type: EXPERIMENTAL
Intervention: Fibrinolysis (tissue plasminogen activator or streptokinase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrinolysis and aspirin combined
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 0
Study: 7046098

Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at night
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29908054

Group type: EXPERIMENTAL
Intervention: Culturally tailored adaptation of the Diabetes Prevention Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25986943

Group type: EXPERIMENTAL
Intervention: 10-day quadruple anti-H. pylori treatment with a single dosage of omeprazole and bismuth
Number of subjects: 184786

Group type: COMPARATOR
Intervention: Lookalike placebos with a single dosage of omeprazole and bismuth
Number of subjects: 184786
Study: 23587468

Group type: EXPERIMENTAL
Intervention: Composite outcome met (39% of patients, 30/76)
Number of subjects: 76
Study: 21848573

Group type: EXPERIMENTAL
Intervention: CBT-I workshops (experimental group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 151
Study: 20586002

Group type: EXPERIMENTAL
Intervention: 3.75 microg antigen with 50% of the standard MF59 dose (group A)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 7.5 microg antigen and 100% standard MF59 dose (group B)
Number of subjects: 123
Study: 17354223

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) administration of yttrium‐90‐labeled murine monoclonal antibody HMFG1 ((90)Y‐muHMFG1)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 447
Study: 15689218

Group type: EXPERIMENTAL
Intervention: 5% Dead Sea salt solution (Mavena(R) Dermaline Mg(46) Dead Sea salt) for 15 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% Dead Sea salt solution
Number of subjects: 0
Study: 12196422

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combination of nateglinide and troglitazone
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 9492967

Group type: EXPERIMENTAL
Intervention: Mailing strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tracking recruitment process yield
Number of subjects: 0
Study: 8129216

Group type: EXPERIMENTAL
Intervention: Open challenge testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-blind testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled oral challenge test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elimination-challenge test
Number of subjects: 0
Study: 2774259

Group type: EXPERIMENTAL
Intervention: liquids, up to 5 ml/kg + placebo (glucose water 0.2 ml/kg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: liquids, up to 5 ml/kg + ranitidine 2 mg/kg in glucose water 0.2 ml/kg
Number of subjects: 88

Group type: COMPARATOR
Intervention: placebo only
Number of subjects: 88

Group type: COMPARATOR
Intervention: ranitidine only
Number of subjects: 88
Study: 4645896

Group type: EXPERIMENTAL
Intervention: Lung perfusion scanning using radioactive particles
Number of subjects: 6
Study: 30880075

Group type: EXPERIMENTAL
Intervention: Substitutional repairs (dorsal grafts)
Number of subjects: 2098

Group type: EXPERIMENTAL
Intervention: Excisional repairs
Number of subjects: 2098

Group type: EXPERIMENTAL
Intervention: Single-stage dorsal repairs
Number of subjects: 2098
Study: 27919361

Group type: EXPERIMENTAL
Intervention: Refined carbohydrate (CARB) diet for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA) diet for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SAFA) diet for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (SAFA)
Number of subjects: 0
Study: 24924587

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 614

Group type: COMPARATOR
Intervention: No Digoxin
Number of subjects: 614
Study: 22591460

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery within an enhanced recovery programme
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conventional open resection of colorectal cancer within an enhanced recovery programme
Number of subjects: 202
Study: 20044673

Group type: EXPERIMENTAL
Intervention: Hip resurfacing with Metasul articulation and titanium plasma-sprayed coating
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total hip replacement with titanium CLS/Spotorno femoral components and titanium AlloFit acetabular components
Number of subjects: 0
Study: 19056791

Group type: EXPERIMENTAL
Intervention: Protocols
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Publications
Number of subjects: 70
Study: 16710349

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin
Number of subjects: 86

Group type: COMPARATOR
Intervention: 30 g cholestyramine
Number of subjects: 86
Study: 12610252

Group type: EXPERIMENTAL
Intervention: Higher perceived coercion scores during hospitalization and at follow-ups
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Higher perceived coercion scores
Number of subjects: 117
Study: 11127083

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valproic acid (VPA)
Number of subjects: 0
Study: 8973074

Group type: EXPERIMENTAL
Intervention: 5-year family counseling program (10 times/year)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 160
Study: 8199503

Group type: EXPERIMENTAL
Intervention: Requiring signed consent for influenza vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mailed reminder letters and information packages in patients' charts
Number of subjects: 0
Study: 3373260

Group type: EXPERIMENTAL
Intervention: 24-hour infusion of weekly fluorouracil (5-FU) at a dose of 750 mg/m2 incrementally increased to 3,400 mg/m2
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 24-hour infusion of weekly fluorouracil (5-FU) plus N-(phosphonacetyl)-L-aspartic acid (PALA) administered as an IV bolus over 15 minutes at a fixed dose of 250 mg/m2
Number of subjects: 52
Study: 30912860

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Monitor-Only (MO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) and Monitor-Only (MO)
Number of subjects: 22
Study: 29173854

Group type: EXPERIMENTAL
Intervention: BioCosmetic (Forestadent, 0.017 in)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Titanol (Forestadent, 0.016 in)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TP Aesthetic (TP Orthodontics, 0.014 in)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tooth Tone (Ortho Organizers, 0.016 in)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: BioCosmetic
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Titanol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TP Aesthetic
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tooth Tone
Number of subjects: 150
Study: 26212672

Group type: EXPERIMENTAL
Intervention: 0.3% saline
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 0.45% saline
Number of subjects: 151

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 151
Study: 23315907

Group type: EXPERIMENTAL
Intervention: Chronotropic Index (CI) < 0.6
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Chronotropic Index (CI)
Number of subjects: 1118
Study: 21318931

Group type: EXPERIMENTAL
Intervention: Computer-based HIV intervention (two 60-minute sessions)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control session of general health information
Number of subjects: 135
Study: 19690066

Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg daily for 16 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo for 16 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 13
Study: 17125718

Group type: EXPERIMENTAL
Intervention: Right radial approach
Number of subjects: 351

Group type: COMPARATOR
Intervention: Left radial approach
Number of subjects: 351
Study: 15574090

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 24
Study: 11585270

Group type: EXPERIMENTAL
Intervention: Arm A: Ondansetron 8 mg i.v. at 4-h intervals plus dexamethasone 20 mg i.v. from the start of CT, followed by dexamethasone 5 mg i.v. every 12 h until CT was complete.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Arm B: Same treatment as arm A but with ondansetron 8 mg i.v. given at 24-h intervals.
Number of subjects: 400
Study: 9101974

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excellent hygienic conditions and advanced surgical techniques
Number of subjects: 0
Study: 1712952

Group type: EXPERIMENTAL
Intervention: Day case management
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional in-patient management
Number of subjects: 50
Study: 6500902

Group type: EXPERIMENTAL
Intervention: Bornaprine 8 mg daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bornaprine (various rising doses)
Number of subjects: 25
Study: 31413233

Group type: EXPERIMENTAL
Intervention: Oral intake of Hericium erinaceus for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 30589045

Group type: EXPERIMENTAL
Intervention: OxyContin 10 mg orally, adjusted according to pain relief
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standardized nursing intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 26511964

Group type: EXPERIMENTAL
Intervention: IminoNorm® (mulberry leaf extract)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24157459

Group type: EXPERIMENTAL
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 50
Study: 20884888

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 29
Study: 19136369

Group type: EXPERIMENTAL
Intervention: Golimumab (50, 100, or 200 mg)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 309
Study: 17188080

Group type: COMPARATOR
Intervention: Standard D2 lymphadenectomy
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Extended D2+ lymphadenectomy
Number of subjects: 275
Study: 15077258

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical exercise (PE)
Number of subjects: 0